# Polyzois Makras

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3942743/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 118 papers | 3,196 citations | 185998 28 h-index | 174990 52 g-index |
| 118 all docs | 118 docs citations | 118 times ranked | 3553 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet Journal of Rare Diseases, 2013, 8, 72. | 1.2 | 281 |
| 2 | Clinical Features of 24 Patients With Reboundâ€Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. Journal of Bone and Mineral Research, 2017, 32, 1291-1296. | 3.1 | 270 |
| 3 | Irisin in metabolic diseases. Endocrine, 2018, 59, 260-274. | 1.1 | 178 |
| 4 | Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocrine-Related Cancer, 2005, 12, 683-699. | 1.6 | 122 |
| 5 | Endocrine manifestations in Langerhans cell histiocytosis. Trends in Endocrinology and Metabolism, 2007, 18, 252-257. | 3.1 | 111 |
| 6 | Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. Journal of Bone and Mineral Research, 2019, 34, 2220-2228. | 3.1 | 103 |
| 7 | THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. European Journal of Endocrinology, 2018, 179, R31-R45. | 1.9 | 94 |
| 8 | Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review. Journal of Clinical Medicine, 2021, 10, 152. | 1.0 | 89 |
| 9 | Expression of microRNAs that regulate bone turnover in the serum of postmenopausal women with low bone mass and vertebral fractures. European Journal of Endocrinology, 2017, 176, 169-176. | 1.9 | 86 |
| 10 | High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clinical Endocrinology, 2009, 71, 772-778. | 1.2 | 76 |
| 11 | Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. European Journal of Endocrinology, 2017, 176, 677-683. | 1.9 | 70 |
| 12 | Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Therapeutics and Clinical Risk Management, 2012, 8, 295. | 0.9 | 69 |
| 13 | International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood, 2022, 139, 2601-2621. | 0.6 | 63 |
| 14 | Novel therapies for osteoporosis. Metabolism: Clinical and Experimental, 2015, 64, 1199-1214. | 1.5 | 62 |
| 15 | Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly. Clinical Endocrinology, 2007, 67, 917-922. | 1.2 | 60 |
| 16 | Evolving radiological features of hypothalamo-pituitary lesions in adult patients with Langerhans cell histiocytosis (LCH). Neuroradiology, 2006, 48, 37-44. | 1.1 | 58 |
| 17 | Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clinical Endocrinology, 2013, 79, 499-503. | 1.2 | 52 |
| 18 | Skeletal Diseases in Cushingâ€™s Syndrome: Osteoporosis versus Arthropathy. Neuroendocrinology, 2010, 92, 60-64. | 1.2 | 51 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1206-1213. | 1.8 | 48 |
| 20 | Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-Head Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3206-3212. | 1.8 | 46 |
| 21 | Bazedoxifene for the treatment of osteoporosis. Expert Opinion on Pharmacotherapy, 2019, 20, 1201-1210. | 0.9 | 42 |
| 22 | Bone disease in primary hyperparathyroidism. Metabolism: Clinical and Experimental, 2018, 80, 57-65. | 1.5 | 40 |
| 23 | Medical treatment of hypercalcaemia. Hormones, 2009, 8, 83-95. | 0.9 | 37 |
| 24 | Off-label uses of denosumab in metabolic bone diseases. Bone, 2019, 129, 115048. | 1.4 | 37 |
| 25 | Effect of 4 weeks of basic military training on peripheral blood leucocytes and urinary excretion of catecholamines and cortisol. Journal of Sports Sciences, 2005, 23, 825-834. | 1.0 | 33 |
| 26 | Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 514-523. | 2.9 | 33 |
| 27 | Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society. Bone, 2019, 127, 401-418. | 1.4 | 33 |
| 28 | Combination and sequential treatment in women with postmenopausal osteoporosis. Expert Opinion on Pharmacotherapy, 2020, 21, 477-490. | 0.9 | 33 |
| 29 | The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4155-e4162. | 1.8 | 31 |
| 30 | Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. Bone, 2012, 50, 1130-1134. | 1.4 | 30 |
| 31 | Outbreak of Meningococcal Disease after an Influenza B Epidemic at a Hellenic Air Force Recruit Training Center. Clinical Infectious Diseases, 2001, 33, e48-e50. | 2.9 | 28 |
| 32 | The 2018 Guidelines for the diagnosis and treatment of osteoporosis in Greece. Archives of Osteoporosis, 2019, 14, 39. | 1.0 | 28 |
| 33 | Incidence of hip fractures in Greece during a 30-year period: 1977â€“2007. Osteoporosis International, 2013, 24, 1579-1585. | 1.3 | 27 |
| 34 | The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. Bone, 2020, 138, 115478. | 1.4 | 26 |
| 35 | Circulating Periostin Levels do not Differ Between Postmenopausal Women with Normal and Low Bone Mass and are not Affected by Zoledronic Acid Treatment. Hormone and Metabolic Research, 2014, 46, 145-149. | 0.7 | 25 |
| 36 | The diagnosis and differential diagnosis of endogenous Cushing?s syndrome. Hormones, 2006, 5, 231-250. | 0.9 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Denosumab in treatment-naÃ¯ve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers. Metabolism: Clinical and Experimental, 2015, 64, 1291-1297. | 1.5 | 24 |
| 38 | Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. Journal of Bone and Mineral Metabolism, 2016, 34, 447-456. | 1.3 | 24 |
| 39 | Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. Hormones, 2011, 10, 174-195. | 0.9 | 23 |
| 40 | Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation. Bone Reports, 2020, 12, 100267. | 0.2 | 22 |
| 41 | Spontaneous Gonadotrophin Deficiency Recovery in an Adult Patient with Langerhans Cell Histiocytosis (LCH). Pituitary, 2005, 8, 169-174. | 1.6 | 21 |
| 42 | BISPHOSPHONATES IN LANGERHANS CELL HISTIOCYTOSIS: AN INTERNATIONAL RETROSPECTIVE CASE SERIES. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016033. | 0.5 | 21 |
| 43 | Coexistence of Gravesâ€™ disease, papillary thyroid carcinoma and unilateral benign struma ovarii: Case report and review of the literature. Metabolism: Clinical and Experimental, 2013, 62, 1350-1356. | 1.5 | 20 |
| 44 | Normal Growth and Muscle Dysfunction in X-Linked Hypophosphatemic Rickets Associated with a Novel Mutation in the PHEX Gene. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1386-1389. | 1.8 | 19 |
| 45 | Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. Bone, 2019, 120, 44-49. | 1.4 | 19 |
| 46 | Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations. Maturitas, 2021, 147, 19-25. | 1.0 | 19 |
| 47 | No Effect of Rosuvastatin in the Zoledronate-Induced Acute-Phase Response. Calcified Tissue International, 2011, 88, 402-408. | 1.5 | 18 |
| 48 | Extra-skeletal effects of bisphosphonates. Metabolism: Clinical and Experimental, 2020, 110, 154264. | 1.5 | 18 |
| 49 | Carcinoid syndrome and carcinoid crisis secondary to a metastatic carcinoid tumour of the lung: a therapeutic challenge. European Journal of Gastroenterology and Hepatology, 2007, 19, 1154-1159. | 0.8 | 17 |
| 50 | Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Expert Opinion on Investigational Drugs, 2015, 24, 145-157. | 1.9 | 17 |
| 51 | Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment. Expert Opinion on Therapeutic Targets, 2015, 19, 299-306. | 1.5 | 16 |
| 52 | Pagetâ€™s Disease of Bone and Calcium Homeostasis: Focus on Bisphosphonate Treatment. Experimental and Clinical Endocrinology and Diabetes, 2011, 119, 519-524. | 0.6 | 15 |
| 53 | Reduced bone mineral density in adult patients with Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2012, 58, 819-822. | 0.8 | 15 |
| 54 | Serum 25-hydroxyvitamin D status, quantitative ultrasound parameters, and their determinants in Greek population. Archives of Osteoporosis, 2018, 13, 111. | 1.0 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Cardiovascular risk factors in adult patients with multisystem Langerhans-cell histiocytosis: evidence of glucose metabolism abnormalities. QJM - Monthly Journal of the Association of Physicians, 2007, 101, 31-40. | 0.2 | 14 |
| 56 | Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis. Metabolism: Clinical and Experimental, 2017, 69, 107-111. | 1.5 | 14 |
| 57 | Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments. Expert Opinion on Investigational Drugs, 2017, 26, 1137-1144. | 1.9 | 13 |
| 58 | Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment. Osteoporosis International, 2013, 24, 2127-2132. | 1.3 | 12 |
| 59 | Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview. Hormones, 2019, 18, 65-70. | 0.9 | 12 |
| 60 | The annual incidence of Langerhans cell histiocytosis among adults living in Greece. Pediatric Blood and Cancer, 2020, 67, e28422. | 0.8 | 12 |
| 61 | Is Serum IL-17A a Useful Systemic Biomarker in Patients With Langerhans Cell Histiocytosis?. Molecular Therapy, 2012, 20, 6-7. | 3.7 | 11 |
| 62 | Cladribine therapy in adults with advanced Langerhans cell histiocytosis. Leukemia and Lymphoma, 2013, 54, 1541-1543. | 0.6 | 11 |
| 63 | Langerhans cell histiocytosis and pituitary function. Endocrine, 2015, 48, 728-729. | 1.1 | 11 |
| 64 | Bone metabolism in Langerhans cell histiocytosis. Endocrine Connections, 2018, 7, R246-R253. | 0.8 | 11 |
| 65 | Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?. Metabolism: Clinical and Experimental, 2019, 93, 100-102. | 1.5 | 11 |
| 66 | Serum Profile of microRNAs Linked to Bone Metabolism During Sequential Treatment for Postmenopausal Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2885-e2894. | 1.8 | 11 |
| 67 | Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell Histiocytosis. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E618-E621. | 1.8 | 10 |
| 68 | A case report of subacute thyroiditis during pregnancy: difficulties in differential diagnosis and changes in cytokine levels. Gynecological Endocrinology, 2011, 27, 384-390. | 0.7 | 9 |
| 69 | Performance of the Mini Nutritional Assessment Score in the Detection of Vitamin D Status in an Elderly Greek Population. Hormone and Metabolic Research, 2012, 44, 896-899. | 0.7 | 9 |
| 70 | Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough. Journal of Clinical Densitometry, 2021, 24, 338-340. | 0.5 | 9 |
| 71 | Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study. Cancers, 2021, 13, 1257. | 1.7 | 9 |
| 72 | Rationale for the Application of RANKL Inhibition in the Treatment of Langerhans Cell Histiocytosis. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E282-E286. | 1.8 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Expression of Circulating MicroRNAs Linked to Bone Metabolism in Chronic Kidney Disease-Mineral and Bone Disorder. Biomedicines, 2020, 8, 601. | 1.4 | 8 |
| 74 | Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation. Calcified Tissue International, 2021, 108, 587-594. | 1.5 | 8 |
| 75 | Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis. Bone, 2009, 44, 766-771. | 1.4 | 7 |
| 76 | Papillary thyroid microcarcinoma presenting as lymph node metastasis â€“ a diagnostic challenge: case report and systematic review of literature. Hormones, 2012, 11, 419-427. | 0.9 | 7 |
| 77 | Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?. Calcified Tissue International, 2018, 103, 107-108. | 1.5 | 7 |
| 78 | Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation. Journal of Clinical Densitometry, 2021, 24, 591-596. | 0.5 | 7 |
| 79 | Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients. Bone Reports, 2021, 15, 101128. | 0.2 | 7 |
| 80 | Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation. Endocrine, 2020, 69, 516-518. | 1.1 | 7 |
| 81 | The role of cytokines and adipocytokines in zoledronateâ€•induced acute phase reaction in postmenopausal women with low bone mass. Clinical Endocrinology, 2012, 77, 816-822. | 1.2 | 6 |
| 82 | Evaluation of the first fracture liaison service in the Greek healthcare setting. Archives of Osteoporosis, 2017, 12, 3. | 1.0 | 6 |
| 83 | Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. Hormones, 2018, 17, 573-579. | 0.9 | 6 |
| 84 | Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis. Bone, 2022, 154, 116209. | 1.4 | 6 |
| 85 | Lessons learned from the management of Hungry Bone Syndrome following the removal of an Atypical Parathyroid Adenoma. Journal of Musculoskeletal Neuronal Interactions, 2019, 19, 379-384. | 0.1 | 6 |
| 86 | Systemic and endocrine manifestations of Langerhansâ€™ cell histiocytosis: current concepts in diagnosis and management. Expert Review of Endocrinology and Metabolism, 2007, 2, 773-783. | 1.2 | 5 |
| 87 | Experience gained from the implementation of the fracture liaison service in Greece. Archives of Osteoporosis, 2020, 15, 12. | 1.0 | 5 |
| 88 | Gender Predilection in Sporadic Parathyroid Adenomas. International Journal of Molecular Sciences, 2020, 21, 2964. | 1.8 | 5 |
| 89 | Denosumab and bisphosphonates: Rivals or potential â€œpartnersâ€? A â€œhybridâ€•molecule hypothesis. Medical Hypotheses, 2011, 77, 109-111. | 0.8 | 4 |
| 90 | Bisphosphonates or denosumab discontinuation and risk of fractures. Maturitas, 2017, 102, 75. | 1.0 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Management of parathyroid disorders: recommendations of the working group of the Bone Section of the Hellenic Endocrine Society. Hormones, 2020, 19, 581-591. | 0.9 | 4 |
| 92 | GH deficiency in adults. Hormones, 2003, 2, 217-228. | 0.9 | 4 |
| 93 | Langerhans' cell histiocytosis in an adult patient manifested as recurrent skull lesions and Diabetes Insipidus. Hormones, 2004, 3, 59-64. | 0.9 | 4 |
| 94 | Growth without growth hormone (GH): A case report. Hormones, 2004, 3, 259-265. | 0.9 | 4 |
| 95 | Prevalence and patterns of anti-osteoporotic drug use based on 2019 real-world nationwide data in Greece. Archives of Osteoporosis, 2022, 17, . | 1.0 | 4 |
| 96 | Adult Langerhans Cell Histiocytosis and the Skeleton. Journal of Clinical Medicine, 2022, 11, 909. | 1.0 | 3 |
| 97 | Distinctive growth pattern in a patient with a delayed diagnosis of Langerhansâ€™ cell histiocytosis. Pituitary, 2012, 15, 28-32. | 1.6 | 2 |
| 98 | Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity. Metabolism: Clinical and Experimental, 2017, 71, 198-201. | 1.5 | 2 |
| 99 | Hypoparathyroidism: is it that easy to treat?. Hormones, 2019, 18, 55-63. | 0.9 | 2 |
| 100 | Circulating microRNAs Related to Bone Metabolism in HIV-Associated Bone Loss. Biomedicines, 2021, 9, 443. | 1.4 | 2 |
| 101 | Î™risin levels in postmenopausal women with an incident hip fracture. Endocrine, 2021, 73, 719-722. | 1.1 | 2 |
| 102 | Questions and facts regarding denosumab discontinuation among postmenopausal women. Expert Opinion on Drug Safety, 2021, 20, 499-501. | 1.0 | 2 |
| 103 | Periostin and sclerostin levels in juvenile Pagetï¿½s disease. Clinical Cases in Mineral and Bone Metabolism, 2017, 14, 269. | 1.0 | 2 |
| 104 | Bisphosphonate Therapy in Langerhans Cell Histiocytosis: An International Retrospective Descriptive Study. Blood, 2015, 126, 2209-2209. | 0.6 | 2 |
| 105 | Prevalence of the BRAF <sup>V600E</sup> mutation in Greek adults with Langerhans cell histiocytosis. Pediatric Hematology and Oncology, 2022, 39, 540-548. | 0.3 | 2 |
| 106 | The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis. Bone, 2022, 158, 116354. | 1.4 | 2 |
| 107 | Skeletal implications of isolated bone marrow mastocytosis. Haematologica, 2011, 96, e27-e27. | 1.7 | 1 |
| 108 | Fracture risk among treatment-naÃ¯ve postmenopausal women with osteopenia in Greece: results from the â€œACROSSâ€•study. Archives of Osteoporosis, 2020, 15, 163. | 1.0 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Circulating and Tissue Expression Profile of <scp>MicroRNAs</scp> in Primary Hyperparathyroidism Caused by Sporadic Parathyroid Adenomas. JBMR Plus, 2021, 5, e10431. | 1.3 | 1 |
| 110 | Changes in the relative expression of circulating microRNAs linked to bone metabolism in HIV-infected Individuals with low bone mass. Endocrine Abstracts, 0, , . | 0.0 | 1 |
| 111 | OUP accepted manuscript. European Journal of Orthodontics, 2021, , . | 1.1 | 1 |
| 112 | Development and validation of an osteoporosis treatment questionnaire (OSTREQ) evaluating physiciansâ€™ criteria in the choice of treatment. Hormones, 2016, 15, 413-422. | 0.9 | 0 |
| 113 | OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis. Journal of the Endocrine Society, 2020, 4, . | 0.1 | 0 |
| 114 | Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion. Endocrine, 2021, 73, 223-225. | 1.1 | 0 |
| 115 | Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid. Journal of Clinical Endocrinology and Metabolism, 2016, 101, L89-L90. | 1.8 | 0 |
| 116 | SUN-LB65 Circulating Micrornas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis. Journal of the Endocrine Society, 2020, 4, . | 0.1 | 0 |
| 117 | Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass. Journal of Musculoskeletal Neuronal Interactions, 2019, 19, 253-257. | 0.1 | 0 |
| 118 | To screen or not to screen for osteoporosis amongst post-menopausal women with one prior osteoporotic fracture in Greece. Aging Clinical and Experimental Research, 0, , . | 1.4 | 0 |